OS Therapies begins UK conditional approval application for Herlystic
OSTX•OS Therapies initiated a UK conditional marketing authorization application for Herlystic to prevent or delay recurrence in fully resected pulmonary metastatic osteosarcoma, with submission acceptance expected in the fourth quarter of 2026 and a potential early market access decision in early 2027.
1. UK application
OS Therapies initiated a UK conditional marketing authorization application for Herlystic to prevent or delay recurrence in fully resected pulmonary metastatic osteosarcoma. The company expects the submission to be accepted in the fourth quarter of 2026 and a potential MHRA early market access decision in early 2027.
